At 8.9% CAGR, Middle East & Africa Neurorehabilitation Devices Market is Projected to be Worth US$ 64.28 million by 2031, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa neurorehabilitation devices market was valued at US$ 32.50 million in 2023 and is expected to reach US$ 64.28 million by 2031, registering a CAGR of 8.9% from 2023 to 2031. Growing number of clinical studies on neurorehabilitation devices and increasing prevalence of neurological diseases are among the critical factors attributed to drive the Middle East & Africa neurorehabilitation devices market growth.

Patients suffering from neurological diseases such as stroke, Parkinson's Disease, multiple sclerosis (MS), Alzheimer's disease, and cerebral palsy require neurorehabilitation devices to improve their motor skills, cognitive abilities, and overall quality of life. Stroke is a leading cause of long-term disability and reduces mobility in half of stroke survivors aged 65 and older. As per the Global Stroke Fact Sheet 2022, every year, there are more than 12.2 million new strokes. One in four people over 25 are likely to have a stroke in their lifetime. The factsheet also stated that there are more than 101 million people currently living across the globe who have already experienced a stroke. Neurorehabilitation devices are widely used to improve memory and communication difficulties and reduce neuropsychiatric symptoms, thereby helping improve the quality of life of dementia patients. Per the World Health Organization fact sheet in 2023, globally, more than 55 million people have dementia, and approximately 10 million new cases are diagnosed every year. The increasing prevalence of neurological diseases worldwide creates a burden on healthcare systems, bolstering the demand for neurorehabilitation devices.

On the flip side, high costs associated with neurorehabilitation devices hamper the growth of Middle East & Africa neurorehabilitation devices market.

By product type, the Middle East & Africa neurorehabilitation devices market is segmented into neurorobotic system, brain computer interface, non-invasive stimulators, and wearable devices. The brain computer interface segment held 52.6% share of Middle East & Africa neurorehabilitation devices market share in 2023, amassing US$ 17.09 million. It is projected to garner US$ 36.22 million by 2031 to register 9.8% CAGR during 2023-2031.

In terms of application, the Middle East & Africa neurorehabilitation devices market is segmented into stroke, traumatic brain injury, spinal cord injury, Parkinson's Disease, cerebral palsy, and others. The stroke segment held 48.6% share of Middle East & Africa neurorehabilitation devices market share in 2023, amassing US$ 15.78 million. It is projected to garner US$ 32.69 million by 2031 to register 9.5% CAGR during 2023-2031.

By end user, the Middle East & Africa neurorehabilitation devices market is segmented into contract rehabilitation centers, hospitals & clinics, and home care. The hospitals & clinics segment held 55.9% share of Middle East & Africa neurorehabilitation devices market share in 2023, amassing US$ 18.17 million. It is projected to garner US$ 39.07 million by 2031 to register 10.0% CAGR during 2023-2031.

Based on country, the Middle East & Africa neurorehabilitation devices market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that Saudi Arabia captured 41.3% share of Middle East & Africa neurorehabilitation devices market in 2023. It was assessed at US$ 13.43 million in 2023 and is likely to hit US$ 26.18 million by 2031, registering a CAGR of 8.7% during 2023-2031.

Key players operating in the Middle East & Africa neurorehabilitation devices market are Abbott Laboratories; BIONIK; BioXtreme Ltd; Blackrock Microsystems Inc; Ekso Bionics Holdings Inc; EMOTIV; Hocoma AG; Medtronic Plc; Renishaw Plc; and Tyromotion GmbH, among others.

• April 2024, Cryptocurrency company Tether invested $200 million into Blackrock Neurotech to take a majority stake in the Brain Computer Interface (BCI) company.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com